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background: The implantable Cardioverter-defibrillator (ICD) is an effective treatment for patients with persistent, drug-refractory non-ischemic 
cardiomyopathies (NI-CM) at risk of sudden cardiac death (SCD) due to sustained ventricular arrhythmias (VAs). The wearable Cardioverter-
Defibrillator (WCD) is often used in patients with low ejection fractions (EF) and other clinical features suggestive of risk of SCD, but not yet 
candidates for an ICD.
method: We reviewed a national database of NI-CM patients prescribed a WCD. The database contained demographic data, initial EF, reason for 
WCD prescription, compliance and usage data, any detected arrhythmias and therapies and reason for discontinuing the WCD. Statistical analyses 
were performed using SAS v9.3.
result: Of the 127 patients, 112 were men (88%) and 15 were women (12%). The mean age was 52.6 ± 10.9 years with a mean ejection fraction 
of 20.2 ± 7.6%. Main presenting symptoms were shortness of breath (62.2%), chest pain (11.8%) and syncope (6.7%). Baseline rhythm was atrial 
fibrillation in 29%. Fifteen percent of patients were on anti-arrhythmic drugs. The patients wore WCD for 68.9 days with average use of 16.8 hours 
per day. The most common reasons for discontinuing WCD were improvement in EF or ICD implantation. Eight patients (7%) received appropriate 
WCD shocks. There were 11 deaths (10%) over 100 days follow-up period -only 4 during the WCD administration period, none of them were due to 
WCD failure. No relationship was found between initial EF and appropriate WCD shocks.
conclusion: NI-CM has a significant risk of death over the next few weeks after initial diagnosis. The WCD was used with high compliance rate and 
delivered appropriate therapy in 7% of patients. The study suggests that a WCD can be a reasonable temporary therapy for prevention of SCD in NI-
CM where patients may have a good chance of recovery of EF.
